CancerDrs

Lymphoma clinical trials in Arkansas

7 actively recruiting lymphoma trials at 5 sites across Arkansas.

Data from ClinicalTrials.gov · last refreshed

Phase 3 Recruiting NIH

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma.…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT04269902
Sites in Arkansas:
  • Mercy Hospital Fort Smith — Fort Smith, Arkansas
  • CHI Saint Vincent Cancer Center Hot Springs — Hot Springs, Arkansas
  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro — Jonesboro, Arkansas
View on ClinicalTrials.gov →
Phase 3 Recruiting NIH

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

This phase III trial compares the effect of adding immunotherapy (brentuximab vedotin and nivolumab) to standard treatment (chemotherapy with or without radiation) to the standard treatment alone in improving survival in patients with stag…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05675410
Sites in Arkansas:
  • Arkansas Children's Hospital — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 3 Recruiting Industry

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

The purpose of the current study is to evaluate the efficacy and safety of \[177Lu\]Lu-DOTA-TATE plus octreotide long-acting release (LAR) versus octreotide LAR alone in newly diagnosed patients with somatostatin receptor positive (SSTR+),…

Sponsor: Novartis Pharmaceuticals
NCT ID: NCT06784752
Sites in Arkansas:
  • Highlands Oncology Group — Fayetteville, Arkansas
View on ClinicalTrials.gov →
Phase 2 Recruiting NIH

Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia

This phase II trial tests the addition of venetoclax and/or blinatumomab to usual chemotherapy for treating infants with newly diagnosed acute lymphoblastic leukemia (ALL) with a KMT2A gene rearrangement (KMT2A-rearranged \[R\]) or without…

Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06317662
Sites in Arkansas:
  • Arkansas Children's Hospital — Little Rock, Arkansas
View on ClinicalTrials.gov →
Phase 2 Recruiting Industry

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

Researchers are looking for ways to treat germinal center B-cell-like diffuse large B-cell lymphoma (GCB DLBCL). DLBCL is a fast-growing blood cancer that affects B-cells. GCB is a type of DLBCL that affects young B-cells that are still ma…

Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06890884
Sites in Arkansas:
  • Genesis Cancer and Blood Institute ( Site 0193) — Hot Springs, Arkansas
View on ClinicalTrials.gov →
Phase 1, Phase 2 Recruiting Academic/Other

TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

The purpose of this study is to improve upon the TINI study treatment. The study will test the ability of a type of immunotherapy called blinatumomab to clear persistent leukemia. Blinatumomab targets CD19 which is located on the leukemia …

Sponsor: Tanja Andrea Gruber
NCT ID: NCT05848687
Sites in Arkansas:
  • Arkansas Children's Hospital — Little Rock, Arkansas
View on ClinicalTrials.gov →
Recruiting Industry

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…

Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Arkansas:
  • Massive Bio SYNERGY-AI site — Little Rock, Arkansas
View on ClinicalTrials.gov →

Medical disclaimer: This page aggregates public ClinicalTrials.gov data. It is not medical advice. Always confirm eligibility and enrollment details with the trial site or your oncologist.

Source: ClinicalTrials.gov API v2 · Last checked: 2026-10-12